Contact
Morgan Anderson-Crannage, Ph.D., is an investigator with expertise in inflammation, immunology, and computational biology. Together with the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, he conducts research on genetic engineering of natural killer cell immunotherapeutics for the treatment of childhood cancer. With a strong foundation in both wet-lab and computational methodologies, his work emphasizes the integration of high-dimensional genomic datasets with functional validation to uncover biologically meaningful mechanisms.
His doctoral training was completed at New York Medical College in the lab of Mitchell S. Cairo, M.D., where his work centered on applying single-cell RNA sequencing to understand pathologies underlying Recessive Dystrophic Epidermolysis Bullosa and identify novel therapeutic targets. Prior to his academic appointment, Dr. Anderson-Crannage held positions at Hackensack University Medical Center and the Vitalant Stem Cell Laboratory, where he gained experience in clinical and translational research settings.
Education
Ph.D., Cell Biology and Anatomy, New York Medical College
Bachelor of Science, Biology, SUNY Purchase College
Areas of Expertise
Cell Biology
Immunology
Publications
- Cairo MS, Lee DA, Vella L, Liao Y, Schaefer E, Flower A, Li Y, Anderson-Crannage M, van de Ven C, Harrison L, Morris E, Wang Y, Manglani M, Qi Y, Tedesco J, Shenoy S, Dvorak CC, Cooke KR, Verneris MR, Kapoor N, Goebel S, Elgarten CW, Bunin NJ, Talano JA. Genomic and Immunomic Characterization, Safety and Efficacy of Related Donor-Derived Cytotoxic T-Lymphocytes (CTLs) in Immunocompromised Recipients with Medically Refractory Adv and CMV Infection: On Behalf of the Viral CTL Consortium (VIRCTLC). Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy. 2026 February; 32(2):S93-S94.
- Hirani R, Anderson-Crannage M, Goldberg C, Lodescar RJ, Etienne M. Gender Disparity Trends in Surgical Specialties: A 12-Year Analysis. J Surg Res. 2025 Dec;316:151-157. doi: 10.1016/j.jss.2025.10.042. Epub 2025 Nov 28. PubMed PMID: 41317592.
- Liao Y, Ramirez M, Tian M, Abdallah S, Anderson-Crannage M, Schaefer E, Marcondes M, Sezgin Y, Lee DA, Cairo MS. 642 Synergistic anti-leukemic effect of NKTR-255 and TGFβ-imprinted CD33. CAR natural killer cells. Journal for immunotherapy of cancer. 2025 November; 13(Suppl 2).
- Tian M, Liao Y, Luo W, Ramirez M, Zhu H, Pan J, Anderson-Crannage M, Schaefer ES, Ayello JS, Cassady KA, Saini U, Cripe TP, Lee DA, Marcondes MA, Cairo MS. 650 Enhanced cytotoxicity of anti-ROR1 CAR NK cells against glioblastoma via combined treatment with oncolytic virus and NKTR-255. Journal for immunotherapy of cancer. 2025 November; 13(Suppl 2).
- Anderson-Crannage M, Tian M, Ramirez M, Pan J, Schaefer E, Liao Y, Cairo MS. Identification of the MIF-CD74/CD44 signaling axis as a therapeutic target in pediatric Acute Myeloid Leukemia. Blood. 2025 November; 146:6786.
- Liao Y, Tian M, Abdallah S, Ramirez M, Pan J, Anderson-Crannage M, Schaefer E, Flower A, Marcondes M, Sezgin Y, Lee D, Cairo M. Enhancing CD33. CAR NK cell therapy for acute myeloid leukemia through TGFβ imprinting and NKTR-255. Blood. 2025 November; 146:2330.
- Anderson-Crannage M, Nyström A, Hirani R, Schaefer E, Hochberg B, Kann R, Pan J, Tian M, Zhu H, Luo W, Ayello J, Cairo MS, Liao Y. Inflammatory modulation by cord blood stem cells prevented digit deformation in recessive dystrophic epidermolysis bullosa. Mol Ther. 2025 Nov 5;33(11):5427-5441. doi: 10.1016/j.ymthe.2025.08.038. Epub 2025 Aug 28. PubMed PMID: 40883988; PubMed Central PMCID: PMC12628145.
Teaching Responsibilities
- Medical Histology Instructor, NYMC 2022-2024
